News Release September 26, 2020 Neovasc Reducer Therapy for Refractory Angina Marks 300th-Patient Milestone in Germany NASDAQ, TSX: NVCN VANCOUVER, MINNEAPOLIS and FRANKFURT, September 25, 2020 - Neovasc, Inc. (`Neovasc` or the `Company`) (NASDAQ, TSX: NVCN), today announced that the 300th patient in Germany has been treated with the Neovasc Reducer™, a medical device designed to treat patients with refractory angina. `This is an important milestone that underscores the growing penetration of Reducer in Germany`s cardiovascular market,` said Fred Colen, President and Chief Executive Officer of Neovasc. `We are seeing a steady increase in adoption and are gratified that we can contribute to...
|
